STOCK TITAN

PDS Biotechnology CEO's 16.6M options need approval

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

PDS Biotechnology Corp President and CEO Frank Bedu-Addo was granted two employee stock-option awards on November 16, 2026: 2,698,978 options, fully vested and exercisable, and 16,556,733 options, subject to stockholder approval of the company’s 2026 Equity Incentive Plan. Both awards have an exercise price of $0.9241 and expire November 16, 2036. The larger award is not exercisable before approval and, if approved, vests in equal monthly installments over four years beginning December 16, 2026, subject to continued service. If approval is not obtained under the grant terms, that option is to be surrendered for cancellation.

Insider BEDU-ADDO FRANK
Role President/CEO
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) F1 2,698,978 $0.00 $0.00
Grant/Award Employee Stock Option (Right to Buy) F2 16,556,733 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (Right to Buy) — 19,255,711 options (Direct)
Holdings Before and After: Employee Stock Option (Right to Buy), 0 to 19,255,711 options (Direct)
Footnotes (2)
  1. F1. The option is fully vested and exercisable.
  2. F2. The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, the shares subject to the option shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation.
Options awarded 2,698,978 options Fully vested and exercisable award granted November 16, 2026
Options awarded 16,556,733 options Award granted November 16, 2026, subject to stockholder approval
Exercise price $0.9241 per option Applies to both employee stock-option awards
Expiration date November 16, 2036 Both employee stock-option awards
Vesting period 4 years Larger award, contingent on stockholder approval and continued service
fully vested and exercisable technical
"The option is fully vested and exercisable."
stockholder approval regulatory
"subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan"
Stockholder approval is formal consent given by a company’s shareholders, usually through a vote at a meeting or by proxy, for major actions such as mergers, asset sales, changes to corporate structure, or amendments to governance rules. Investors pay attention because the vote can enable or block steps that materially change a company’s direction, ownership or value—like neighbors voting to allow a major renovation that would alter a building’s use and worth.
Nasdaq Marketplace Rule 5635(c) regulatory
"under Nasdaq Marketplace Rule 5635(c)"
vest in equal monthly installments technical
"shares subject to the option shall vest in equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happens to the 16,556,733-option PDSB award if shareholders do not approve the plan?

If stockholder approval of PDS Biotechnology Corp’s 2026 Equity Incentive Plan is not obtained under the grant terms, Frank Bedu-Addo shall surrender the option to the company for cancellation.

When does the 16,556,733-option PDSB award vest?

If stockholders approve the plan, the options vest in equal monthly installments over four years beginning December 16, 2026, subject to Frank Bedu-Addo’s continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BEDU-ADDO FRANK

(Last)(First)(Middle)
C/O PDS BIOTECHNOLOGY CORPORATION
303A COLLEGE ROAD EAST

(Street)
PRINCETON NEW JERSEY 08540

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President/CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$0.924111/16/2026A2,698,978 (1)11/16/2036Common Stock2,698,978$0.002,698,978D
Employee Stock Option (Right to Buy)$0.924111/16/2026A16,556,733 (2)11/16/2036Common Stock16,556,733$0.0016,556,733D
Explanation of Responses:
1. The option is fully vested and exercisable.
2. The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, the shares subject to the option shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation.
/s/ Spencer Brown, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading